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Abstract
Background: Clinicians often experience extrahepatic metastases associated with hepatocellular carcinoma (HCC),
even if no evidence of intrahepatic recurrence after treatment is observed. We investigated the pretreatment
predictors of extrahepatic metastases in HCC patients.
Methods: Patients diagnosed with HCC without evidence of extrahepatic metastases were prospectively enrolled.
We evaluated the correlation between extrahepatic metastases and pretreatment clinical variables, including serum
tumor markers.
Results: A total of 354 patients were included. Seventy-six patients (21%) had extrahepatic metastases during the
observation period (median, 25.3 months; range, 0.6-51.3 months). Cox regression multivariate analysis showed that
serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) production levels, the intrahepatic tumor
stage, platelet count, and portal vein thrombosis were independent risk factors for extrahepatic metastases. Patients
with a PIVKA-II production ≥ 300 mAU/mL had a 2.7-fold (95% confidence interval; 1.5-4.8; P < 0.001) and 3.7-fold
(95% confidence interval; 2.0-6.6; P < 0.001) increased risk for extrahepatic metastases after adjustment for stage,
platelet count, alpha-fetoprotein ≥ 400 ng/mL, and portal vein thrombosis according to the AJCC and BCLC
staging systems, respectively.
Conclusion: PIVKA-II production levels might be a good candidate predictive marker for extrahepatic HCC
metastases, especially in patients with smaller and/or fewer tumors in the liver with in stages regardless of serum
alpha-fetoprotein.
Keywords: Protein induced by vitamin K absence or antagonist-II, hepatocellular carcinoma, metastases, predictive
marker
Background
Hepatic resection and liver transplantation are an estab-
lished curative treatment for early stage HCC patients
[1-3]. However, few good candidates are available for
surgical resection and liver transplantation due to surgi-
cal risks associated with liver cirrhosis and the limited
number of available donors, respectively. On the other
hand, alternative therapeutic approaches, such as percu-
taneous ethanol injection (PEI) or radiofrequency abla-
tion (RFA) for small HCCs [3,4] and transarterial
chemoembolization (TACE) for multinodular hypervas-
cular HCC, have been widely applied for the treatment
of patients with HCC [5,6]. Although an increased num-
ber of therapeutic options may improve treatment
results for small HCCs, a significant proportion of
patients that undergo these procedures have intrahepatic
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de novo recurrence or metastases [7,8]. It was reported
that the percentages of intrahepatic metastases and mul-
ticentric occurrences found after initial treatment of
small hepatocellular carcinomas less than 2 cm in dia-
meter was 23.7% after 1 year, 64.5% after 3 years, and
76.1% after 5 years [8].
Sometimes, clinicians experience extrahepatic metas-
tases even if a primary lesion is not found after surgical
resection or liver transplantation. In addition, extrahepa-
tic metastases may occur after locoregional therapies for
early stage HCC and a long-term remission. As recent
advances have been made in our understanding of the
molecular pathways of HCC, the metastatic potential of
early HCC has been confirmed by gene expression
assessment using microarray analysis [9]. In addition, an
oral multikinase inhibitor that targets serine/threonine
and tyrosine kinase receptors has been shown to result
in decreased tumor growth and inhibition of angiogen-
esis in patients with HCC [10-12]. If we could determine
the patients at increased risk for extrahepatic metastases
at an early timepoint with specific predictive factors, we
could select good candidates for surgical treatment and
prevent unnecessary liver transplantation or surgical
resection. Furthermore, agents targeted to the appropri-
ate tumors at the appropriate time could control the
development of distant metastases. However, the factors
that predict metastases, including specific tumor mar-
kers, are not yet identified for patients with HCC.
In our previous pilot study of patients who were fol-
lowed after treatment of HCC, those with high serum
levels of protein induced by vitamin K absence or antago-
nist-II production (PIVKA-II) during follow up showed
an increased rate of development of metastases at an
early stage, even if they had well-controlled primary liver
lesions without portal vein thromboses. In this study, we
prospectively investigated the pretreatment predictors of
extrahepatic metastases in HCC patients.
Methods
Patients
Four hundred seventy-six consecutive patients who were
diagnosed with HCC between September 2005 and July
2008 at Seoul National University Hospital in Seoul,
Korea, were included. Patients whose serum levels of
PIVKA-II and AFP at the time of diagnosis were not avail-
able (64 patients), those who had metastases at the time of
diagnosis (43), those who were untreated (15), were
excluded. Any patients who may have been taking warfarin
would have also been excluded, though none of the
patients in this study were treated with it. Accordingly,
354 patients were enrolled into this prospective cohort
study, which was approved by the Institutional Review
Board of Seoul National University Hospital. We obtained
written informed consents from all patients enrolled.
Diagnosis
A definitive diagnosis of HCC was confirmed based on
typical hypervascular radiologic features and serum
alpha-fetoprotein (AFP) levels or histologic findings by
AASLD guidelines. All patients underwent testing for
liver function, hepatitis B and C profiles, and serum
AFP and PIVKA-II levels; a chest PA and dynamic CT
of the abdomen and pelvis were obtained. If nodules
were noted on the chest PA, a chest CT or biopsy were
performed to exclude lung metastases. Patients com-
plaining of bone pain had a bone scan. Follow-up after
the initial treatment consisted of blood tests, monitoring
of tumor markers, chest PA, and a dynamic CT includ-
ing the pelvis once or twice within 6 months.
AFP and PIVKA-II determinations
The serum concentration of PIVKA-II was assayed by
an enzyme-linked immunoassay kit using Eitest (cut-off
value, 40 mAU/mL; Sanko Junyaku Co., Tokyo, Japan).
The AFP was measured using the AFP IRMA system
(cut-off value, 20 ng/mL; Immunotech, Beckman Coul-
ter, Fullerton, CA, USA). Both the serum AFP and
PIVKA-II were measured when patients were initially
diagnosed with HCC.
Variables
The following variables, measured at the time of diagno-
sis, were included in the analysis to identify predictors
of extrahepatic metastases: age; gender; tumor stage;
tumor size; Child-Pugh class; serum levels of AFP,
PIVKA-II, albumin, and total bilirubin; and prothombin
time (PT). We analyzed two different tumor stage sys-
tems (the American Joint Committee on Cancer [AJCC]
and the Barcelona Clinic Liver Cancer [BCLC] staging
systems) to evaluate the correlation between extrahepa-
tic metastases and other clinical variables [13,14].
Tumor markers were used with both continuous and
dichotomized variables with cut-off values for AFP at ≥
400 ng/mL and PIVKA-II at ≥ 300 mAU/mL when we
analyzed the predictive factors for extrahepatic metas-
tases, other clinical factors, and tumor markers.
Locoregional treatment for HCC
Patients were treated by PEI or RFA for lesions < 4 cm
in diameter. Hepatic resection was carried out if the
tumors were small and the patients had good liver func-
tion without significant co-morbidities. TACE was per-
formed in patients with multiple hypervascular
intrahepatic tumors.
Statistics analysis
We evaluated the correlation between extrahepatic
metastases, serum levels of tumor markers (AFP and
PIVKA-II), and clinical findings according to the AJCC
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and BCLC staging systems. Univariate analyses to iden-
tify predictors of extrahepatic metastases were per-
formed using the Kaplan-Meier method or Cox-
regression and the variables at the time of diagnosis.
The differences between groups were tested for signifi-
cance using the log-rank test. The variables which were
significantly associated with extrahepatic metastases in
the univariate analyses were included in the multivariate
analysis with the Cox proportional hazards regression
model using a forward stepwise approach to identify
independent predictors of extrahepatic metastases. All
statistical analyses were performed using SPSS 12.0
(SPSS, Inc., Chicago, IL, USA). For all tests, a P-value <
0.05 was considered statistically significant.
Results
Baseline characteristics
Two hundred sixty-five among 354 patients (75%) were
males, and the median age was 56 years (range, 19-82
years). The median duration of follow-up of all patients
was 25.3 months (range, 0.6-51.3 months). The baseline
characteristics of the study population for all patients
are shown in Table 1. The percentages of patients who
were seropositive for hepatitis B virus surface antigen
and anti-hepatitis C virus antibody were 95.2% and
3.7%, respectively. The percentages of patients in Child-
Pugh classes A, B, and C were 69.8%, 26.0%, and 4.2%,
respectively. At the time of diagnosis, the proportion of
patients with an AFP ≥ 400 ng/mL was 31.1%, and 28%
of patients had a PIVKA-II ≥ 300 mAU/mL. The med-
ian values for platelet count and PT (%) were 121, 000/
mm3 and 83%, respectively; the median values for albu-
min and bilirubin were 3.7 g/dL and 1.0 mg/dL, respec-
tively. Of 354 patients, 76 (21%) had extrahepatic
metastases during the observation period. The most
common places for metastases to occur are the lungs
(57%), bones (20%), metastatic lymph nodes (36%), adre-
nal gland (7%), peritoneal seeding (5%), spleen (3%), and
the brain (3%).
Predictive factors for extrahepatic metastases
All patients
Of the entire cohort of patients, the AJCC (P < 0.001)
and BCLC tumor stage (P < 0.001), serum PIVKA-II
level (P < 0.001), AFP level (P = 0.008), portal vein
thrombosis (P < 0.001), and platelet count (P = 0.0004)
were significantly associated with the presence of extra-
hepatic metastases based on univariate analyses (Table
2). However, age, bilirubin and albumin levels, and
prothorombin time (PT) failed to show a significant
association with extrahepatic metastases. When we
applied the AJCC and BCLC staging systems in the sub-
sequent Cox-regression multivariate analysis, PIVKA-II
levels with continuous variables (P = 0.001 and P <
0.001), portal vein thrombosis (P = 0.126 and P <
0.001), tumor stage (P < 0.001 and P < 0.001), and plate-
let count (P = 0.019 and P = 0.011) were shown to be
independent risk factors for extrahepatic metastases,
respectively. We performed multivariate analysis with
Table 1 Baseline characteristics
Characteristics n = 354
Age (years)† 56 (19-82)
Sex Male 265 (74.9%)
Etiology of chronic liver
disease
Hepatitis B virus 337 (95.2%)
Hepatitis C virus 13 (3.7%)




≥ 5 cm 93 (26.2%)
Tumor number 1 216 (61.0%)
2-3 57 (16.1%)
> 3 81 (22.8%)




BCLC Tumor stage A: Early 224 (63.1%)
B: Intermediate 48 (13.5%)
C: advanced 67 (18.9%)
D: end-stage 15 (4.2%)
AJCC Tumor stage I 170 (48.0%)
II 86 (24.6%)
III 98 (27.4%)
Portal vein thrombosis Present 65 (18.4%)
Child-Pugh class A 247 (69.8%)
B 92 (26.0%)
C 15 (4.2%)
Serum AFP 52.0 (2.2-3, 560,
000)
(ng/mL) < 400 244 (68.9%)
≥ 400 110 (31.1%)
Serum PIVKA-II 54.0 (2.0-42, 780)
(mAU/mL) < 300 255 (72.0%)
≥ 300 99 (28.0%)
Laboratory parameters Platelet count (103/μL)† 121 (18-610)
PT (%)† 83 (36-126)
AST (IU/L)† 50 (17-2036)
ALT (IU/L)† 43 (6-1775)
Albumin (g/dL)† 3.7 (2.1-5.0)
Total bilirubin (mg/dL)† 1.0 (0.3-31.8)
Values in the column are represented as number of patients (%) or median
value (range).
Abbreviation: TACE, transarterial chemoembolization; RFA, radiofrequency
ablation; PEI, percutaneous ethanol injection; AFP, alpha-fetoprotein; PIVKA-II,
Protein induced by vitamin K absence or antagonist-II; PT, prothrombin time;
AST, aspartate aminotransaminase; ALT, alanine aminotransferase.
† all were used with continuous variables.
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stage, portal vein thrombosis, platelet count, and tumor
markers according to cut-off values of tumor markers
for AFP (≥ 400 ng/mL) and PIVKA-II (≥ 300 mAU/mL).
It was consistently shown that PIVKA-II ≥ 300 mAU/
mL, portal vein thrombosis (in BCLC) and platelet
count were independent risk factors for extrahepatic
metastases based on multivariate analysis (Table 3).
However, AFP did not significantly increase the hazard
ratio of extrahepatic metastasis in any combination of
tumor markers based on multivariate analysis. The
patients with a PIVKA-II ≥ 300 mAU/mL had a 2.7-fold
(95% confidence interval [CI], 1.535-4.812, P = 0.001)
and a 3.7-fold (95% confidence interval [CI], 2.073-
6.560, P < 0.001) in AJCC and BCLC hazard ratios of
extrahepatic metastases, respectively, when the those
with AFP ≥ 400 and PIVKA-II ≥ 300 in Cox regression
analysis after adjustment for portal vein thrombosis, pla-
telet count, and stage were applied. Figure 1 shows the
time to extrahepatic metastases based on Cox regression
analysis in patients with a PIVKA-II ≥ 300 in AJCC and
BCLC stages after adjustment for portal vein thrombo-
sis, AFP ≥ 400 platelet count, and stage.
Subgroup analysis for extrahepatic metastases according
to AJCC tumor stage
To determine whether the serum levels of PIVKA-II
predict HCC metastases in patients with different
tumor stages, we stratified the patients according to
tumor stage based on the AJCC staging system and
evaluated the risk factors for extrahepatic metastases.
When we analyzed the subgroups with all variables
included at the time of diagnosis according to the
AJCC tumor stage, the serum PIKVA-II (P < 0.001)
and platelet count (P = 0.022) in stage I, serum AFP
(P = 0.018) and PIVKA-II (P = 0.008) in stage II, and
serum PIVKA-II (P = 0.023) and platelet count (P =
0.031) in stage III were risk factors for extrahepatic
metastases in univariate analysis. In multivariate analy-
sis, only the serum PIVKA-II level was an independent
predictive factor of extrahepatic metastases in patients
with stage I (P = 0.001), II (P = 0.023), and III (P =
0.028) disease. In particular, a serum PIVKA-II level ≥
300 mAU/mL had a 8.8-fold (95% CI, 2.538-30.303, P
< 0.001), 3.4-fold (95% CI, 1.179-9.523, P = 0.025), and
2.2-fold (95% CI, 1.086-4.504, P = 0.025) increased risk
among patients with stages I, II, and III disease com-
pared to patients with serum PIVKA-II levels < 300
mAU/mL in multivariate analysis after adjustment for
AFP ≥ 400, PT, and platelet count. All other variables,
including albumin, PT, AST, ALT, and bilirubin, were
not associated with extrahepatic metastases in sub-
group analysis according to stage. Table 4 shows the
univariate and multivariate analysis for extrahepatic
metastases with serum AFP, PIVKA-II, PT, and platelet
count according to stage. The Kaplan curves for extra-
hepatic metastases according to AJCC stage are shown
in Figure 2a (stage I, P < 0.001), 2b (stage II, P =
0.004), and 2c (stage III, P = 0.020). The median time
to extrahepatic metastases in those with a PIVKA-II ≥
300 mAU/mL was 37 months in stage II and 10
months in stage III, respectively, on Kaplan curves,
whereas stage I patients with a PIVKA-II ≥ 300 mAU/
mL did not reach the median time to extrahepatic
metastases during follow up periods.
Table 2 Univariate analysis in overall patients
Characteristics Hazard ratio (95% CI) P value*
Age (years)† 0.981 (0.958-1.004) 0.106
Sex 0.937 (0.558-1.576) 0.807
Etiology of CLD 0.361 (0.090-1.439) 0.149
Portal vein thrombosis 6.716 (4.169-10.819) < 0.001
Child-Pugh class 1.264 (0.833-1.918) 0.270
AJCC Tumor stage 4.759 (3.410-6.643) < 0.001








Serum PIVKA-II (≥ 300 mAU/mL) 8.701 (5.394-14.035) < 0.001
Platelet count (≤ 130 × 103/μL) 2.319 (1.454-3.698) 0.0004
PT (≤ 80%) 0.737 (0.460-1.179) 0.203
Albumin (≥ 3.5 g/dl) 0.790 (0.498-1.252) 0.316
Total bilirubin (≥ 1.5 mg/dL) 1.174 (0.287-4.796) 0.823
Values in the column are represented as number of patients (%) or median
value (range).
Abbreviation: CLD, chronic liver disease; AFP, alpha-fetoprotein; PIVKA-II,
Protein induced by vitamin K absence or antagonist-II; PT, prothrombin time;
AST, aspartate aminotransaminase; ALT, alanine aminotransferase.
*P-values for each clinical variable calculated using Cox regression analysis.
†all were used with continuous variables.
Table 3 Multivariate analysis in overall patients
according to AJCC or BCLC tumor stage
Characteristics Hazard ratio (95% CI) P value*
AJCC Tumor stage 2.775 (1.815-4.243) < 0.001
Portal vein thrombosis 1.573 (0.912-2.715) 0.103
Serum AFP (≥ 400 ng/mL) 1.153 (0.688-1.919) 0.584
Serum PIVKA-II (≥ 300 mAU/mL) 2.718 (1.535-4.812) 0.001
Platelet count (≤ 130 × 103/μL) 1.830 (1.130-2.964) 0.014
BCLC Tumor stage 1.210 (1.047-1.400) 0.010
Portal vein thrombosis 1.934 (1.094-3.422) 0.023
Serum AFP (≥ 400 ng/mL) 1.470 (0.888-2.433) 0.133
Serum PIVKA-II (≥ 300 mAU/mL) 3.688 (2.073-6.560) < 0.001
Platelet count (≤ 130 × 103/μL) 1.911 (1.187-3.076) 0.008
Abbreviation: AFP, alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K
absence or antagonist-II;
*P-values for each clinical variable calculated using Cox regression analysis.
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Subgroup analysis for extrahepatic metastases according
to BCLC tumor stage
When we analyzed the subgroups with all variables
included at the time of diagnosis according to the BCLC
tumor stage, the serum PIKVA-II (P < 0.001) and serum
AFP (P = 0.023) in stage A, and serum PIVKA-II (P =
0.047) in stage C were risk factors for extrahepatic
metastases in univariate analysis. In multivariate analy-
sis, the serum PIVKA-II level (P < 0.001) and AFP level
(P = 0.049) in stage A and serum PIVKA-II (P = 0.033)
in stage C were independent predictive factors of extra-
hepatic metastases. In BCLC staging B and D HCC
patients, PIVKA-II was not a significant factor asso-
ciated with extrahepatic metastases (P = 0.225, P =
0.678) in multivariate analysis. In particular, a serum
PIVKA-II level ≥ 300 mAU/mL had a 8.4-fold (95% CI,
3.424-20.408, P < 0.001) and 3.2-fold (95% CI, 1.098-
9.174, P = 0.033) increased risk among patients with
stages A and C disease compared to patients with serum
PIVKA-II levels < 300 mAU/mL. All other variables,
including albumin, PT, platelet count, AST, ALT, and
bilirubin, were not associated with extrahepatic metas-
tases in subgroup analysis according to stage. The
Kaplan curves for extrahepatic metastases according to
BCLC stage are shown in Figure 2d (stage A, P < 0.001),
2e (stage B, P = 0.216), and 2f (stage C, P = 0.037). The
median time to extrahepatic metastases in those with a
PIVKA-II ≥ 300 mAU/mL was 31.5 in stage B and 8.4
months in stage C on Kaplan curves, whereas stage A
patients with a PIVKA-II ≥ 300 mAU/mL did not reach
the median time to extrahepatic metastases during fol-
low up periods.
Subgroup analysis according to treatment modality
The number of patients with extrahepatic metastasis was
59 (28.9%) for the TACE group, 7 (9.4%) for the PEIT
group, 2 (4.7%) for the RFA group, and 8 (23.5%) for
the surgery group. We analyzed the predictive factors
for extrahepatic metastasis according to treatment mod-
ality. Serum PIVKA-II level (P < 0.001), AFP level (P =
0.027), portal vein thrombosis (P < 0.001), platelet count
(P < 0.001), and PT (P = 0.018) were significantly asso-
ciated with the presence of extrahepatic metastases in
univariate analyses in the TACE group. It was consis-
tently shown that PIVKA-II and platelet count were
independent risk factors for extrahepatic metastases
based on multivariate analysis. Patients with PIVKA-II ≥
300 mAU/mL had a 6.4-fold increased risk (95% confi-
dence interval [CI], 3.255-12.711, P < 0.001), and those
with platelet count > 130 K had a 1.8-fold increased risk
(95% confidence interval [CI], 1.084-3.154, P = 0.024) in
the TACE group. AFP level and portal vein thrombosis
Figure 1 The median time to extrahepatic metastases in patients with a PIVKA-II ≥ 300 mAU/mL. The cumulative metastasis-free rate was
analyzed in a multivariate Cox regression model in patients with a PIVKA-II ≥ 300 in AJCC (1a; Hazard Ratio, HR = 2.7, 95% confidence interval
[CI] = 1.535-4.812, adjusted P = 0.001) and BCLC stage BCLC (1b: HR = 3.7, 95% CI = 2.073-6.560, adjusted P < 0.001) adjusting for such
covariates as platelet count, AFP ≥ 400, portal vein thrombosis, and stage.
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did not appear statistically significant for extrahepatic
metastasis in a multivariate analysis.
The serum PIVKA-II level (P = 0.007) and AFP level
(P = 0.032) were significantly associated with the pre-
sence of extrahepatic metastases based on univariate
analyses in patients receiving surgery. However, only the
PIVKA-II level (P = 0.070) had an independent risk fac-
tor for extrahepatic metastases in multivariate analysis.
A serum PIVKA-II level ≥ 300 mAU/mL had an 8.7-fold
increased risk (95% CI, 4.793-15.699, P < 0.001) for
extrahepatic metastasis. The serum PIVKA-II level (P =
0.012) and AFP level (P = 0.002) were significantly asso-
ciated with the presence of extrahepatic metastases in
patients receiving PEIT. A serum PIVKA-II level ≥ 300
mAU/mL had a 23.1-fold increased risk (95% CI, 2.175-
245.979, P = 0.009) for extrahepatic metastasis, while a
serum AFP level ≥ 400 mAU/mL had a 5.2-fold
increased risk (95% CI, 1.000-27.742, P = 0.050). The
serum PIVKA-II level (P = 0.019) was significantly asso-
ciated with the presence of extrahepatic metastases in
patients receiving RFA. However, no statistical signifi-
cance manifested in patients with a serum PIVKA-II
level ≥ 300 mAU/mL, which is due to the small number
of patients.
Subgroup analysis according to serum AFP and PIVKA-II
levels
To determine whether a specific combination of tumor
markers is associated with the risk for metastases, we
stratified the patients into 5 groups using the values of
AFP and PIVKA-II at the time of diagnosis: group 1
patients were those who had a low AFP and a low
Table 4 Univariate and multivariate analysis according to stage
Characteristics Hazard ratio (95% CI)
in univariate analysis




Serum AFP (≥ 400 ng/mL) 1.523 (0.412-5.629) 0.528 1.490 (0.394-5.649) 0.556
Serum PIVKA-II (≥ 300 mAU/mL) 9.317 (2.736-30.453) < 0.001 8.771 (2.538-30.303) 0.001
PT (≤ 80%) 1.862 (0.503-6.896) 0.352 0.746 (0.164-3.397) 0.705
Platelet count (≤ 130 × 103/μL) 4.608 (1.250-16.949) 0.022 4.948 (1.097-22.322) 0.037
AJCC stage II
Serum AFP (≥ 400 ng/mL) 3.484 (1.233-9.803) 0.018 2.832 (0.983-8.196) 0.054
Serum PIVKA-II (≥ 300 mAU/mL) 3.984 (1.466-10.989) 0.008 3.355 (1.179-9.523) 0.023
PT (≤ 80%) 1.198 (0.434-3.305) 0.728 1.167 (0.382-3.564) 0.786
Platelet count (≤ 130 × 103/μL) 1.164 (1.413-3.267) 0.773 0.820 (0.265-2.542) 0.732
AJCC stage III
Serum AFP (≥ 400 ng/mL) 1.037 (0.586-1.834) 0.899 1, 164 (0.652-2.078) 0.608
Serum PIVKA-II (≥ 300 mAU/mL) 2.252 (1.116-4.545) 0.023 2.212 (1.086-4.504) 0.028
PT (≤ 80%) 1.192 (0.659-2, 158) 0.561 1.254 (0.685-2.296) 0.464
Platelet count (≤ 130 × 103/μL) 1.934 (1.062-3.522) 0.031 1.868 (1.017-3.428) 0.044
BCLC stage A
Serum AFP (≥ 400 ng/mL) 1.934 (1.094-3.424) 0.023 2.544 (1.003-6.451) 0.049
Serum PIVKA-II (≥ 300 mAU/mL) 9.319 (3.856-22.525) < 0.001 8.403 (3.424-20.408) < 0.001
PT (≤ 80%) 1.845 (0.714-4.761) 0.206 1.098 (0.404-2.9984) 0.854
Platelet count (≤ 130 × 103/μL) 2.127 (0.896-5.050) 0.087 2.055 (0.820-5.153) 0.125
BCLC stage B
Serum AFP (≥ 400 ng/mL) 1.183 (0.502-2.791) 0.701 1.163 (0.482-2.807) 0.737
Serum PIVKA-II (≥ 300 mAU/mL) 1.740 (0.715-4.232) 0.222 1.743 (0.711-4.271) 0.225
PT (≤ 80%) 1.054 (0.443-2.508) 0.905 1.142 (0.448-2.911) 0.782
Platelet count (≤ 130 × 103/μL) 1.243 (0.461-2.710) 0.804 1.072 (0.424-2.712) 0.833
BCLC stage C
Serum AFP (≥ 400 ng/mL) 1.382 (0.656-2.910) 0.394 1.377 (0.610-3.105) 0.440
Serum PIVKA-II (≥ 300 AU/mL) 2.909 (1.015-8.333) 0.047 3.174 (1.098-9.174) 0.033
PT (≤ 80%) 0.800 (0385-1.659) 0.548 0.588 (0.258-1.338) 0.205
Platelet count (≤ 130 × 103/μL) 1.642 (0.790-3.412) 0.184 1.917 (0.893-4.114) 0.095
Abbreviation: AFP, alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence or antagonist-II; PT, prothrombin time.
*P-values for each clinical variable calculated using Cox regression analysis.
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PIVKA-II (AFP < 60 ng/mL and PIVKA-II < 80 mAU/
mL); group 2 had a high AFP and a low PIVKA-II (AFP
≥ 400 ng/mL and PIVKA-II < 80 mAU/mL); group 4
had a low AFP and high PIVKA-II (AFP < 60 ng/mL
and PIVKA-II ≥ 300 mAU/mL); group 5 had a high
AFP and high PIVKA-II (AFP ≥ 400 ng/mL and PIVKA-
II ≥ 300 mAU/mL); and group 3 included other
combinations. The time to extrahepatic metastases
based on the subgroup is presented using a Kaplan-
Meier curve in Figure 3. When the relative risk was
compared by Cox regression analysis, the patients in
group 5 had a 9.7-fold relative risk for extrahepatic
metastases compared to the patients in groups 1, 2, or 3
(95% CI, 5.780-16.393, P < 0.001), and the patients in
Figure 2 The risks for extrahepatic metastases according to serum levels of PIVKA-II were assessed by the Kaplan-Meier method. Risk
of extrahepatic metastases was significantly higher for patients with a serum PIVKA-II level ≥ 300 mAU/mL than for those with PIVKA-II level <
300 mAU/mL among patients with stage I (a, P < 0.001), II (b, P = 0.004), and III (c, P = 0.020) HCC according to AJCC tumor stages and stage A
(d, P < 0.001), B (e, P = 0.216) and C (f, P = 0.037) according to BCLC tumor stages.
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group 4 had a 5.3-fold relative risk compared to the
patients in groups 1, 2, or 3 (95% CI, 2.898-9.803, P <
0.001). Group 4 patients had a 2.7-fold relative risk for
extrahepatic metastases compared to group 2 (95% CI,
1.886-6.134, P = 0.018); however, group 5 patients did
not have an increased risk for extrahepatic metastases
compared to group 4 (RR 1.8 fold, 95% CI, 0.959-3.278,
P = 0.067). These results indicate that PIVKA-II levels
are independently related to extrahepatic metastases
regardless of AFP levels.
Alteration of the PIVKA-II level during follow-up
We investigated the correlation between the change in
the serum PIVKA-II level during follow-up and extrahe-
patic metastases in patients with elevated levels of
PIVKA-II (≥ 80 mAU/mL, 2.0 times the normal PIVKA-
II level). One hundred thirty-three patients had serum
levels of PIVKA-II ≥ 80 AU/mL at the time of diagnosis.
Of these patients, 35 who did not have PIVKA-II level
monitoring after initial management were excluded
from this analysis. The remaining 98 patients were clas-
sified into the following 3 groups according to altera-
tions in PIVKA-II levels during the follow-up periods:
group A included patients in whom serum PIVKA-II
values fell below the normal level after initial manage-
ment and persisted below the normal level during all
follow-up periods (n = 46); group B included patients in
whom serum PIVKA-II levels fell below or above the
normal range transiently compared to the initial value
after treatment and then increased to ≥ 80 mAU/mL (n
= 40); and group C included patients in whom serum
PIVKA-II levels persistently increased above the initial
value (n = 12) after initial treatment. All treatments
were limited to reduce intrahepatic tumor burdens, such
as TACE, RFA, and surgery. Median times to extrahepa-
tic metastases in groups B and C were 10.9 and 5.1
months, respectively (P < 0.001, Figure 4); however,
group C did not decrease to the median time to extra-
hepatic metastases during the follow-up period.
Discussion
The results of this study have shown that the serum
level of PIVKA-II is an independent prognostic factor
for extrahepatic metastases in HCC patients. This asso-
ciation of PIVKA-II with extrahepatic metastases was
maintained in the subgroup analyses, regardless of the
tumor staging system used (AJCC and BCLC). More-
over, in the subgroup analysis involving the combination
of AFP and PIVKA-II, group 4 (high PIVKA-II and low
AFP) and 5 (high PIVKA-II and high AFP) showed an
increased tendency for extrahepatic metastases and a
shorter time to metastases than the other groups.
Figure 3 The risk for extrahepatic metastases according to different combinations of serum AFP and PIVKA-II levels was assessed by
the Kaplan-Meier method.
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Together, these findings suggest that the PIVKA-II
levels are independently related to extrahepatic metas-
tases regardless of serum AFP level and tumor staging;
additionally, they showed a strong association with early
stages with low AFP. This is consistent with prior clini-
cal studies showing that the pre-operative PIVKA-II
level is an independent predictor of microvessel invasion
in post-surgical histology or after liver transplantation
[15-17]. This finding may also be explained by an in
vitro study showing that PIVKA-II stimulates cell prolif-
eration and cell migration of vascular endothelial cells
by binding to the kinase insert domain receptor, alterna-
tively referred to as the vascular endothelial growth fac-
tor receptor-2 [18].
Several prior reports have suggested that PIVKA-II
may be a useful marker for the prediction of portal vein
thrombosis [19-22], as well as the intrahepatic spread of
disease [22]. In addition, our study demonstrated that
PIVKA-II levels may be strongly associated with extra-
hepatic metastases in patients with AJCC stage I and
BCLC stage A who did not have portal vein thrombosis
and invasion.
In the current study, PIVKA-II levels were strongly
associated with extrahepatic metastases, especially in
patients with early stage disease and smaller and/or
fewer tumors compared to those in an advanced stage.
These observations suggest that as the tumor stage
advances, the association between PIVKA-II and the
risk for metastases may be weakened. This can be
explained by the intrahepatic tumor burden, which
itself increases the value of PIVKA-II regardless of the
presence of metastases. This can also be explained by
follow-up data in patients with a high serum PIVKA-II
level at the time of diagnosis. The patient group in
which the serum PIVKA-II values decreased after
intrahepatic tumor management and persisted below
the normal range for PIVKA-II during the follow-up
period could have only had an intrahepatic tumor
before treatment. The high serum PIVKA-II level in
this group reflects an intrahepatic tumor burden only.
However, the patient group in which the serum
PIVKA-II value transiently decreased after intrahepatic
management and then increased after treatment could
have had an intrahepatic tumor and undetected extra-
hepatic metastases before treatment. Thus, the value of
PIVKA-II in this group increased by extrahepatic
tumor growth during the follow-up period, but transi-
ently decreased after intrahepatic tumor management.
The last patient group in which the serum PIVKA-II
value persistently increased, even after treatment,
could have had an undetected higher extrahepatic
tumor burden compared to the intrahepatic tumor;
thus the value of PIVKA-II persistently increased, even
if the intrahepatic tumors were controlled.
Figure 4 The median time to extrahepatic metastases according to the change in the serum PIVKA-II level during follow-up and
extrahepatic metastases in patients with elevated levels of PIVKA-II (P < 0.001).
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Our overall results may be explained by the different
blood supply source to the tumor between intra- and
extra-hepatic HCCs. Liver cells are mainly supplied by
the portal vein, which conveys a sufficient amount of
vitamin K directly by enterohepatic circulation from
intestinal absorption by dietary intake or colonic micro-
flora synthesis. Although intrahepatic HCCs are mainly
supplied by the hepatic artery, intrahepatic HCCs are
also supplied by the portal vein and are able to uptake a
sufficient quantity of vitamin K. However, extrahepatic
metastatic HCCs, such as those in lung and bone,
receive blood from the peripheral circulation, which
probably does not transport an adequate amount of vita-
min K compared to the portal flow. Therefore, we can
assume that HCC cells in extrahepatic metastases can-
not actively synthesize prothrombin due to vitamin K
insufficiency and may consequently increase the serum
level of PIVKA-II. However, there are no studies which
have compared the concentration of vitamin K between
the portal vein and the peripheral blood or hepatic
artery which support the portal vein having a higher
concentration of vitamin K compared to the hepatic
artery or systemic circulation.
In our study, we set the cutoff value for PIVKA-II
levels at 300 mAU/mL and AFP level at 400 which was
determined by the lowest value of ([1 - sensitivity]2 + [1
- specificity]2) as 349 mAU/mL and 420 ng/mL, respec-
tively, by using a receiver operating characteristic curve
of extrahepatic metastasis at 12 months after curative
treatment. The analysis of gene networks associated
with HCCs has shown that specific genotypes are asso-
ciated with the biological characteristics of tumor devel-
opment; for example, the HB subtype has been shown
to be more invasive than the HC subtype [23]. Osteo-
pontin is unique as a well-known gene associated with
HCC metastases and progression [24]. There is no prior
report implicating PIVKA-II as a predictive marker for
extrahepatic metastases. Our study is the first prospec-
tive report to demonstrate an association between
PIVKA-II levels and extrahepatic metastases in HCC
patients. A corollary study is needed to determine
whether a high PIVKA-II level is associated with a spe-
cific subtype of HCC.
Conclusion
PIVKA-II levels might be a good candidate predictive
marker for extrahepatic metastases, especially in patients
with early HCC regardless of AFP.
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